Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alessandro Brigo

Showing results (11-20 of 24) with videos related to

Pageof 3
Sort By:
Npj Drug Discovery|June 30, 2026
SARM1 base-exchange inhibitors induce SARM1 activation and neurodegeneration at low dosesAnisha Mani, Mateusz Mendel, Paul Westwood, et al.
Regulatory Toxicology and Pharmacology : RTP|January 20, 2016
It's difficult, but important, to make negative predictionsRichard V Williams, Alexander Amberg, Alessandro Brigo, et al.
Regulatory Toxicology and Pharmacology : RTP|December 29, 2015
Evaluation of a statistics-based Ames mutagenicity QSAR model and interpretation of the results obtainedChris Barber, Alex Cayley, Thierry Hanser, et al.
Regulatory Toxicology and Pharmacology : RTP|May 15, 2013
Use of in silico systems and expert knowledge for structure-based assessment of potentially mutagenic impuritiesAndreas Sutter, Alexander Amberg, Scott Boyer, et al.
Frontiers in Pharmacology|August 5, 2025
Preclinical pharmacology of alogabat: a novel GABA<sub>A</sub>-α5 positive allosteric modulator targeting neurodevelopmental disorders with impaired GABA<sub>A</sub> signalingGiuseppe Cecere, Theresa M Ballard, Frederic Knoflach, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 16, 2021
Preclinical Characterization of a Next-Generation Brain Permeable, Paradox Breaker BRAF InhibitorJürgen Wichmann, Caroline Rynn, Thomas Friess, et al.
Journal of Medicinal Chemistry|March 18, 2025
Discovery of a Potent SARM1 Base-Exchange Inhibitor with In Vivo EfficacyMaude Giroud, Bernd Kuhn, Sandra Steiner, et al.
Regulatory Toxicology and Pharmacology : RTP|February 16, 2016
Principles and procedures for implementation of ICH M7 recommended (Q)SAR analysesAlexander Amberg, Lisa Beilke, Joel Bercu, et al.
Regulatory Toxicology and Pharmacology : RTP|December 19, 2018
Principles and procedures for handling out-of-domain and indeterminate results as part of ICH M7 recommended (Q)SAR analysesAlexander Amberg, Roxanne V Andaya, Lennart T Anger, et al.
Computational Toxicology (Amsterdam, Netherlands)|April 4, 2022
<i>In Silico</i> Approaches In Carcinogenicity Hazard Assessment: Current Status and Future NeedsRaymond R Tice, Arianna Bassan, Alexander Amberg, et al.
Pageof 3

Showing results (11-20 of 24) with videos related to

Sort By:
Pageof 3
Npj Drug Discovery|June 30, 2026
SARM1 base-exchange inhibitors induce SARM1 activation and neurodegeneration at low dosesAnisha Mani, Mateusz Mendel, Paul Westwood, et al.
Regulatory Toxicology and Pharmacology : RTP|January 20, 2016
It's difficult, but important, to make negative predictionsRichard V Williams, Alexander Amberg, Alessandro Brigo, et al.
Regulatory Toxicology and Pharmacology : RTP|December 29, 2015
Evaluation of a statistics-based Ames mutagenicity QSAR model and interpretation of the results obtainedChris Barber, Alex Cayley, Thierry Hanser, et al.
Regulatory Toxicology and Pharmacology : RTP|May 15, 2013
Use of in silico systems and expert knowledge for structure-based assessment of potentially mutagenic impuritiesAndreas Sutter, Alexander Amberg, Scott Boyer, et al.
Frontiers in Pharmacology|August 5, 2025
Preclinical pharmacology of alogabat: a novel GABA<sub>A</sub>-α5 positive allosteric modulator targeting neurodevelopmental disorders with impaired GABA<sub>A</sub> signalingGiuseppe Cecere, Theresa M Ballard, Frederic Knoflach, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 16, 2021
Preclinical Characterization of a Next-Generation Brain Permeable, Paradox Breaker BRAF InhibitorJürgen Wichmann, Caroline Rynn, Thomas Friess, et al.
Journal of Medicinal Chemistry|March 18, 2025
Discovery of a Potent SARM1 Base-Exchange Inhibitor with In Vivo EfficacyMaude Giroud, Bernd Kuhn, Sandra Steiner, et al.
Regulatory Toxicology and Pharmacology : RTP|February 16, 2016
Principles and procedures for implementation of ICH M7 recommended (Q)SAR analysesAlexander Amberg, Lisa Beilke, Joel Bercu, et al.
Regulatory Toxicology and Pharmacology : RTP|December 19, 2018
Principles and procedures for handling out-of-domain and indeterminate results as part of ICH M7 recommended (Q)SAR analysesAlexander Amberg, Roxanne V Andaya, Lennart T Anger, et al.
Computational Toxicology (Amsterdam, Netherlands)|April 4, 2022
<i>In Silico</i> Approaches In Carcinogenicity Hazard Assessment: Current Status and Future NeedsRaymond R Tice, Arianna Bassan, Alexander Amberg, et al.
Pageof 3